Revvity (NYSE:RVTY) Research Coverage Started at UBS Group

UBS Group started coverage on shares of Revvity (NYSE:RVTY) in a report released on Wednesday morning, MarketBeat reports. The brokerage issued a neutral rating and a $140.00 price target on the stock.

A number of other brokerages have also recently issued reports on RVTY. KeyCorp increased their target price on Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. Sanford C. Bernstein initiated coverage on shares of Revvity in a research note on Friday, June 26th. They set a “market perform” rating and a $115.00 price target for the company. Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. Wolfe Research began coverage on shares of Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Finally, TD Cowen reiterated a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to MarketBeat.com, Revvity has a consensus rating of “Hold” and an average price target of $116.57.

Revvity Stock Performance

Shares of Revvity stock opened at $124.46 on Wednesday. The business has a 50-day simple moving average of $117.71 and a 200 day simple moving average of $103.21. Revvity has a one year low of $81.22 and a one year high of $133.00. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The firm has a market capitalization of $13.89 billion, a price-to-earnings ratio of 59.27, a PEG ratio of 2.20 and a beta of 1.09.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.20. The business had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The company’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts anticipate that Revvity will post 5.36 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio (DPR) is 13.33%.

Institutional Trading of Revvity

Institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System lifted its position in shares of Revvity by 10,607.8% during the 2nd quarter. California State Teachers Retirement System now owns 14,328,063 shares of the company’s stock worth $1,594,140,000 after buying an additional 14,194,254 shares in the last quarter. Jupiter Topco LLC purchased a new position in shares of Revvity in the 2nd quarter worth approximately $961,017,000. BlackRock Inc. bought a new position in shares of Revvity in the second quarter valued at approximately $852,070,000. Wellington Management Group LLP grew its holdings in shares of Revvity by 10,653.8% in the second quarter. Wellington Management Group LLP now owns 865,575 shares of the company’s stock valued at $96,304,000 after acquiring an additional 857,526 shares in the last quarter. Finally, Primecap Management Co. CA purchased a new stake in shares of Revvity during the second quarter valued at approximately $94,921,000. Institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.